Willow Biosciences Inc said it has incorporated life science technology company Inscripta’s Onyx Genome Engineering Platform into its strain engineering workflows.
The move will enable Willow’s team to engineer strains more rapidly to give its researchers invaluable time to focus on intelligent library design and data analysis, the Vancouver-based company said.
The Onyx platform will also accelerate Willow’s genetic editing capabilities and throughput, and bring the commercial development of its FutureGrown molecules much quicker to market.
READ: Willow Biosciences expands its portfolio with a new partnered pharmaceutical project
“Willow is thrilled to seamlessly integrate Inscripta's automated, high-throughput gene-editing platform to shorten our development cycles and empower our scientists to effectively harness the tremendous potential of the entire genome," Dr Trish Choudhary, vice president of Research & Development at Willow Biosciences, said in a statement.
"Technology advancements such as next-generation sequencing have enabled researchers to read genetic information at incredible speed and depth. Inscripta's technology now enables researchers to write genetic information with the same speed and with unparalleled precision, a combination that promises endless possibilities,” she added.
Dr Nandini Krishnamurthy, vice president of Microbial Business Unit at Inscripta noted that the future of the synthetic biology economy is dependent on both large and small companies innovating under increasing pressure to deliver better products, faster, and often with less resources.
“Willow is a great example of how a lean, yet highly innovative organization can rapidly integrate and utilize the Onyx platform," Krishnamurthy said.
Willow develops and produces high-purity ingredients for the personal care, food and beverage, and pharmaceutical markets. Willow's FutureGrown biotechnology platform allows large-scale production with sustainability at its core.
Contact the author at jon.hopkins@proactiveinvestors.com